First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

TL;DR: Targeting the key mediators of nucleocytoplasmic transport in cancer cells represents a novel strategy in cancer intervention with the potential to significantly affect outcomes.

TL;DR: The development of a new class of antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE), are summarized and KPT-330 (selinexor) as an oral agent is showing activities in early clinical trials in both solid tumors and hematological malignancies.

TL;DR: Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) to be developed for clinical use, and preclinical data has demonstrated antineoplastic activity of SINE compounds in many human solid and hematologic malignancies.

TL;DR: The results of the study suggest that patients with decreased 8-oxo-Gua levels and increased 8-Oxo-dG levels in urine 24 h after the first dose should be considered as better responders to the administered chemotherapy, with a lower risk of death.